文献类型：期刊文献

英文题名：Fuzheng Jiedu granules against disease progression among high-risk adults with non-severe COVID-19: a multicenter retrospective cohort study

作者：Hua, Qiaoli[1];Zheng, Danwen[2,3,4];Shui, Jingwei[3];Zhang, Tong[5,6];Qin, Shengle[3];Zhang, Hanhong[7];Yu, Bo[8];Wang, Longde[9];He, Hailang[10];Tan, Xinghua[11];Chen, Qiumin[12];Yang, Yang[13];Heng, Weng[14];Cai, Yihang[2,4];Xu, Xiaohua[2,4];Liu, Qing[2,4,15];Liu, Yuntao[2,4,14];Yang, Rongyuan[2,14,15];Zhang, Zhongde[2,4,14]

第一作者：Hua, Qiaoli

通信作者：Liu, YT[1];Yang, RY[1];Zhang, ZD[1];Liu, YT[2];Zhang, ZD[2];Liu, YT[3];Yang, RY[3];Zhang, ZD[3];Yang, RY[4]

机构：[1]Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Clin Lab, Shenzhen, Peoples R China;[2]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Emergency, Guangzhou, Peoples R China;[3]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China;[4]Guangdong Prov Key Lab Res Emergency TCM, Dept Emergency, Guangzhou, Peoples R China;[5]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Cardiol, Guangzhou, Peoples R China;[6]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Zhens Miscellaneous Dis Sch Lingnan Lingnan Zhensh, Guangzhou, Peoples R China;[7]Hainan Prov Hosp Tradit Chinese Med, Dept Emergency, Haikou, Peoples R China;[8]2 Peoples Hosp Lanzhou, Dept Gen Surg, Lanzhou, Peoples R China;[9]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[10]Jiangsu Prov Hosp Tradit Chinese Med, Dept Resp & Crit Care Med, Nanjing, Peoples R China;[11]Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Tradit Chinese Med, Guangzhou, Peoples R China;[12]Xiamen Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Xiamen, Peoples R China;[13]Dalian Hosp Tradit Chinese Med, Dept Emergency, Dalian, Peoples R China;[14]Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China;[15]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Zhuhai Hosp, Zhuhai, Peoples R China

第一机构：Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Clin Med Coll 4, Dept Clin Lab, Shenzhen, Peoples R China

通信机构：[1]corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Emergency, Guangzhou, Peoples R China;[2]corresponding author), Guangdong Prov Key Lab Res Emergency TCM, Dept Emergency, Guangzhou, Peoples R China;[3]corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China;[4]corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Zhuhai Hosp, Zhuhai, Peoples R China.

年份：2025

卷号：16

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001494279400001)】；

基金：The authors acknowledge all health-care workers involved in the data collection and quality control.

语种：英文

外文关键词：COVID-19; Fuzheng Jiedu granules; traditional Chinese medicine; high-risk patients; disease progression

摘要：Background Fuzheng Jiedu (FZJD) granules are widely used to treat coronavirus disease (COVID-19) since their market approval, but their clinical effectiveness remains uncertain. In this study, we aimed to evaluate the effectiveness of FZJD in reducing disease progression in high-risk adults with COVID-19.Methods A multicenter, retrospective cohort study involving high-risk adults with non-severe COVID-19 was conducted in China from May 2021 to December 2022. The study was registered at the Chinese Clinical Trial Registry (ChiCTR2200058097; https://www.chictr.org.cn/bin/project/edit?pid=160010). Patients were categorized into two groups based on the administration of FZJD granules. The outcomes included disease progression, mechanical ventilation, intensive care unit (ICU) admission, and mortality. Propensity-score analyses and multivariable regression were performed to assess the effectiveness of FZJD granules. The effectiveness was further analyzed in different subgroups.Results A total of 1,644 patients (54.7% female patients; mean age, 62.3 years) were included, with 27.4% (451/1,644) receiving FZJD granules. After propensity score matching (PSM), 320 FZJD granule receivers and 320 non-receivers were matched. Those receiving FZJD granules were associated with lower risks of disease progression [adjusted odds ratio (OR), 0.21; 95% confidence interval (CI), 0.06-0.73], mechanical ventilation (OR, 0.15; 95% CI, 0.03-0.66), and ICU admission (OR, 0.08; 95% CI, 0.01-0.64) than those not receiving FZJD granules. The lower risk of disease progression in the FZJD group was confirmed by multivariable regression analysis and various propensity-score analyses. Furthermore, subgroup analyses demonstrated significant treatment benefits in patients with moderate COVID-19 at admission (no progression to severe disease) or in those who were not fully vaccinated (OR, 0.06; 95% CI, 0.01-0.50).Conclusion FZJD administration was significantly associated with a reduced risk of disease progression in high-risk adults with mild-to-moderate COVID-19.